Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · February 26, 2022

Effects of Canagliflozin and Metformin on Insulin Resistance and Visceral Adipose Tissue in Newly-Diagnosed T2D

BMC Endocrine Disorders


Additional Info

BMC Endocrine Disorders
Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes
BMC Endocr Disord 2022 Feb 10;22(1)37, Z Hao, Y Sun, G Li, Y Shen, Y Wen, Y Liu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading